At Beth Israel Deaconess Medical Center, doctors say a once-fringe treatment for multiple myeloma is starting to look like a legitimate frontline weapon for some patients. CAR T cell therapy is delivering unusually high remission rates, with clinicians reporting dramatic recoveries after a single, intensive infusion in people who had already burned through standard options. The catch: the therapy is complicated, can trigger serious side effects, and is still reserved for carefully selected patients.
Local clinicians describe a "transformational" moment
David Avigan, who directs BIDMC's cancer center, and Jacalyn Rosenblatt, who leads the hospital's cell-therapy program, say what they are seeing in clinic feels different from past incremental gains. Avigan told The Business Journals, "we are living in a time of transformational change," while Rosenblatt said clinicians have "been privileged to see how the discovery work in cancer immunotherapy has directly impacted the lives of our patients."
BIDMC built a local cell-therapy hub
Part of BIDMC's muscle in this space comes from its homegrown manufacturing setup. The Randi and Brian Schwartz Family Cancer Immunotherapy and Cell Manipulation Facility was designed to build and test cell therapies on site, giving teams the ability to engineer CAR T cells and produce experimental vaccines under Good Manufacturing Practice conditions. The on-campus suite and biologics clinic speed up production and let researchers tweak protocols without the delays of offsite manufacturing, according to BIDMC. That local infrastructure is a big reason Boston groups can move quickly from lab findings into real-world patient care.
Regulatory milestones and trial results
CAR T for myeloma is no longer a theoretical future. The FDA has signed off on BCMA-targeting CAR T products for people with relapsed or refractory multiple myeloma, and pivotal trials have reported very high response rates in heavily pretreated patients. In approval documents for idecabtagene vicleucel (Abecma) and ciltacabtagene autoleucel (CARVYKTI), regulators cite overall response rates running from roughly 72 percent up to nearly 98 percent, and they also flag risks such as cytokine release syndrome and neurologic toxicities. Those approvals have brought CAR T into certified hospitals equipped to handle the therapy's unique complications, according to the FDA.
Durable remissions are real, but not universal
Published trial reports and expert reviews have found that many patients achieve deep responses and a meaningful subset reach long-term remission, although results vary by product and by patient. Studies of BCMA-directed CAR T therapy have documented complete response rates as high as roughly two-thirds in certain cohorts, and longer follow-up has shown a fraction of patients remaining progression-free at five years. That points to durable benefit for some, but not all, of those treated. Those findings are detailed in the clinical literature and syntheses of recent trial data, including reporting in the Journal of Clinical Oncology.
Vaccine research and multi-site collaboration
Even as CAR T gains ground, BIDMC investigators are pursuing a complementary path with personalized cancer vaccines that fuse a patient's tumor cells with dendritic cells to expand tumor-reactive immune responses. Avigan and Rosenblatt helped lead a multi-site initiative to share vaccine production protocols so that other centers could adopt the approach. Hospital reporting notes that at least one early patient who received a cell-based strategy in 2017 stayed in remission for five years, according to The Business Journals and explanatory coverage of fusion-vaccine techniques from Blood Cancers Today. The broader goal is to open access to immune-based treatments beyond the small number of major manufacturing hubs.
What is next: solid tumors and safer cells
Researchers say the toughest near-term challenges are cracking solid tumors, dialing down toxicities, and streamlining production so more hospitals can realistically offer CAR T. Groups in Boston and across the country are testing multi-target CAR designs, tweaks to improve cell persistence, and combination strategies aimed at blunting cytokine storms. Experts describe the work as promising but still early, according to the Harvard Gazette. The consensus in the region is that CAR T is evolving from a one-off miracle into a platform technology that will need technical refinements and scaled-up production to reach many more patients.
For now, BIDMC's mix of advanced clinical care, on-site cell manufacturing, and vaccine research helps explain why Boston remains a magnet for next-generation cancer treatment. The mood is one of cautious optimism: clear wins for some patients, coupled with an urgent push to make those successes safer, more reliable, and easier to access.
